Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, ...

SAN FRANCISCO — While generative AI (AI) is being hailed as a game-changer as it sweeps the globe, the concept of “in silico medicine,” or computational medicine, is not exactly a new one.

Insilico Medicine has raised $60 million in fourth-round financing that will help to fund the advancement of more drugs towards the clinical testing stage. The Hong Kong-based startup – one of ...

Hong Kong’s Insilico Medicine has found a way to use AI and deep learning to design, synthesise and validate a novel drug candidate in 46 days – 15 times faster than the best pharma companies.

Insilico Medicine ("Insilico"), a clinical-stage generative AI-driven biotechnology company, has launched a preview version of its draft outline research assistant, Science42:DORA, to streamline ...

After working for years to understand how to apply an artificial intelligence (AI) approach to biotechnology, Insilico Medicine recently announced the discovery of a novel drug target and novel ...

Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making ...

After working for years to understand how to apply an artificial intelligence (AI) approach to biotechnology, Insilico Medicine recently disclosed the discovery of a novel drug target and novel ...

According to the agreement, Vindur Tx will pay Optic up to $17.5 million for its proprietary technology to explore new ways of addressing previously "undruggable" targets in difficult-to-treat cancers ...

Insilico Medicine, a clinical stage biotech company powered by generative artificial intelligence (AI), is connecting biology, chemistry and clinical trials analysis using next-generation AI systems.